Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Moderna
MRNA
|
$2.75B |
| 2 |
Coupang
CPNG
|
$1.09B |
| 3 |
Trade Desk
TTD
|
$793M |
| 4 |
BioNTech
BNTX
|
$736M |
| 5 |
Bilibili
BILI
|
$639M |
Top Sells
| 1 |
Tesla
TSLA
|
$7.41B |
| 2 |
Alphabet (Google) Class C
GOOG
|
$1.39B |
| 3 |
Meta Platforms (Facebook)
META
|
$880M |
| 4 |
Amazon
AMZN
|
$773M |
| 5 |
NIO
NIO
|
$619M |
Sector Composition
| 1 | Consumer Discretionary | 31.93% |
| 2 | Healthcare | 19.13% |
| 3 | Technology | 17.13% |
| 4 | Communication Services | 14.58% |
| 5 | Financials | 5.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Medtronic
MDT
$118B
| $35.2M | 0.02% |
298,030
+89,283
| +43% | +$10.5M |
|
202
Cisco
CSCO
$268B
| $34.3M | 0.02% |
663,309
+53,253
| +9% | +$2.75M |
|
|
VEDL
203
DELISTED
Vedanta Limited American Depostary Shares (Each representing four equity shares)
VEDL
| $34M | 0.02% |
2,701,535
+2,269,551
| +525% | +$28.5M |
|
204
Edwards Lifesciences
EW
$47.7B
| $33.9M | 0.02% |
404,957
+124,646
| +44% | +$10.4M |
|
|
SIX
205
DELISTED
Six Flags Entertainment Corp.
SIX
| $32.4M | 0.02% |
696,551
+61,751
| +10% | +$2.87M |
|
206
T Rowe Price
TROW
$23.2B
| $32.2M | 0.02% |
187,919
+10,478
| +6% | +$1.8M |
|
207
Tandem Diabetes Care
TNDM
$834M
| $30.6M | 0.02% |
346,757
+51,312
| +17% | +$4.53M |
|
208
Quanterix
QTRX
$202M
| $30.1M | 0.02% |
+514,012
| New | +$30.1M |
|
|
API
209
Agora
API
$309M
| $29.8M | 0.02% |
591,900
+158,700
| +37% | +$7.98M |
|
210
Dolby
DLB
$6.94B
| $29.6M | 0.02% |
300,224
+7,067
| +2% | +$698K |
|
211
Waters Corp
WAT
$17.3B
| $27.6M | 0.02% |
97,212
+4,121
| +4% | +$1.17M |
|
212
Veeco
VECO
$1.42B
| $27.6M | 0.02% |
1,330,677
-3,023
| -0.2% | -$62.7K |
|
213
CEVA Inc
CEVA
$520M
| $27.4M | 0.02% |
487,729
+1,217
| +0.3% | +$68.3K |
|
214
Cullen/Frost Bankers
CFR
$8.28B
| $26.5M | 0.01% |
243,341
+4,004
| +2% | +$435K |
|
215
Bumble
BMBL
$657M
| $25M | 0.01% |
+400,000
| New | +$25M |
|
216
Digimarc
DMRC
$171M
| $24.8M | 0.01% |
834,609
+73,984
| +10% | +$2.19M |
|
217
Royal Caribbean
RCL
$96.4B
| $23.7M | 0.01% |
277,389
+25,389
| +10% | +$2.17M |
|
218
Axogen
AXGN
$718M
| $23.7M | 0.01% |
1,171,734
+9,982
| +0.9% | +$202K |
|
219
Stratasys
SSYS
$863M
| $23M | 0.01% |
887,610
-9,102
| -1% | -$236K |
|
|
UBX
220
DELISTED
Unity Biotechnology
UBX
| $22.8M | 0.01% |
380,301
| – | – |
|
221
American Superconductor
AMSC
$2.2B
| $22M | 0.01% |
1,161,700
+511,400
| +79% | +$9.7M |
|
222
Butterfly Network
BFLY
$378M
| $21.6M | 0.01% |
+1,285,209
| New | +$21.6M |
|
223
Certara
CERT
$1.69B
| $21.5M | 0.01% |
+787,464
| New | +$21.5M |
|
224
FirstCash
FCFS
$6.63B
| $21.2M | 0.01% |
322,343
+29,343
| +10% | +$1.93M |
|
|
NBTX
225
Nanobiotix
NBTX
$418M
| $21M | 0.01% |
1,400,000
| – | – |
|